The DOI matches its Crossref record.
Immune Responses to Therapeutic Proteins in Humans - Clinical Significance, Assessment and Prediction
Abstract
There is a large and increasing number of therapeutic proteins approved for clinical use and many more undergoing preclinical studies and clinical trials in humans. Most of them are human or 'humanized' recombinant molecules. Virtually all therapeutic proteins elicit some level of antibody response, which in some cases, can lead to potentially serious side effects. Therefore, immunogenicity of therapeutic proteins is a concern for clinicians, manufacturers and regulatory agencies. In order to assess immunogenicity of these molecules, appropriate detection, quantitation and characterization of antibody responses are necessary. Immune responses to therapeutic proteins in conventional animal models has not been, except in rare cases, predictive of the response in humans. In recent years there has been a considerable progress in development of computational methods for prediction of epitopes in protein molecules that have the potential to induce an immune response in a recipient. Initial attempts to apply such tools in early development of therapeutic proteins have already been reported. It is expected that computer driven prediction followed by in vitro and/or in vivo testing of any potentially immunogenic epitopes will help in avoiding, or at least minimizing, immune responses to therapeutic proteins.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Challenges in the development of high protein concentration formulations
Shire, S. J., Shahrokh, Z., & Liu, J. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20079 · Cited by 882
Engineering novel binding proteins from nonimmunoglobulin domains
Binz, H. K., Amstutz, P., & Plückthun, A. (2005) · Nature Biotechnology · doi:10.1038/nbt1127 · Cited by 676
Challenges in the Development of High Protein Concentration Formulations
Shire, S. J., Shahrokh, Z., & Liu, J. (2010) · Current Trends in Monoclonal Antibody Development and Manufacturing · doi:10.1007/978-0-387-76643-0_9 · Cited by 657
Shankar, G., Devanarayan, V., Amaravadi, L., Barrett, Y. C., Bowsher, R., Finco-Kent, D., Fiscella, M., Gorovits, B., Kirschner, S., Moxness, M., et al. (2008) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2008.09.020 · Cited by 613
Self-citationImmunogenicity of protein therapeutics
De Groot, A. S., & Scott, D. W. (2007) · Trends in Immunology · doi:10.1016/j.it.2007.07.011 · Cited by 545
Metadata
- Authors
- Koren, E., Zuckerman, L., & Mire-Sluis, A.
- Venue
- Current Pharmaceutical Biotechnology
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2002-12-01
- Volume
- 3
- Issue
- 4
- Pages
- 349-360
- ISSN
- 1389-2010 (ISSN-L)
- OpenAlex
- W2164309192
- Cited by
- 267
- References
- 0
- FWCI
- 2.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immune Responses to Therapeutic Proteins in Humans - Clinical Significance, Assessment and Prediction. https://app.cochat.ai/papers/10.2174/1389201023378175
- The paper
- Koren, E., Zuckerman, L., & Mire-Sluis, A. (2002). Immune Responses to Therapeutic Proteins in Humans - Clinical Significance, Assessment and Prediction. Current Pharmaceutical Biotechnology. https://doi.org/10.2174/1389201023378175
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.